Compare C3.ai Inc (AI) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
C3.ai Inc vs Cytokinetics Inc — how do they compare? C3.ai Inc trades at $8.9 (market cap $1.39B), while Cytokinetics Inc trades at $84.75 (market cap $11.62B). The key difference: Cytokinetics Inc is far larger — about 8.4× C3.ai Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, C3.ai Inc nearer its low. Which is the better fit depends on your goals.
| AI | CYTK | |
|---|---|---|
Market Cap | $1.39B | $11.62B |
Sector | Technology | Technology |
52-Week High | $29.16 | $87.26 |
52-Week Low | $7.76 | $33.23 |
Enterprise Value | $818.29M | $12.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
C3.ai trades at $8.93, down 1.43% with bearish technical signals. The company shows revenue growth to $389M in 2025 but continues significant losses with -$289M net income. Analyst sentiment is mixed with 21% buy ratings and consensus target of $10.20. Recent developments include board member Jim Hagemann Snabe's appointment as European Commission Special Envoy for Industrial AI.
While revenue growth presents opportunity, persistent losses and negative cash flow pose substantial risk. The stock faces headwinds from unprofitability despite beating some earnings estimates. Upside potential exists if the company can accelerate path to profitability amid growing enterprise AI adoption.
CYTK trades at $85.57, down 1.06% on the day, with a bullish technical signal from moving averages and strong analyst support. The company reported a net loss of $784.96 million in 2025, with revenue of $88.04 million, but recent news highlights the European launch of MYQORZO and upcoming clinical data presentations at the ESC Congress 2026, indicating growth potential.
The outlook for CYTK is driven by product launches and clinical milestones, but high valuation (P/S 98.09) and persistent losses pose risks. Analyst consensus is overwhelmingly bullish with a $110.60 price target, though investors must weigh the speculative nature against execution risks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About C3.ai Inc
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Suite, is a comprehensive application development and runtime environment that is designed to allow customers to rapidly design, develop, and deploy Enterprise AI applications of any type
Read more on AI →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
